Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0308189 on May 21, 2008

Published online before print May 21, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0308189v1
84/2/577    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Cortes, L. M.
Right arrow Articles by Caspi, R. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cortes, L. M.
Right arrow Articles by Caspi, R. R.
(Journal of Leukocyte Biology. 2008;84:577-585.)
© 2008 by Society for Leukocyte Biology

Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells

Lizette M. Cortes*, Dody Avichezer*, Phyllis B. Silver*, Dror Luger*, Mary J. Mattapallil*, Chi-Chao Chan{dagger} and Rachel R. Caspi*,1

* Laboratories of Immunoregulation and
{dagger} Retinal Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

1 Correspondence: Laboratory of Immunology, NEI, NIH, 10 Center Drive, 10/10N222, Bethesda, MD 20893-1857, USA. E-mail: rcaspi{at}helix.nih

ABSTRACT

We identified inhibitory peptide analogs (IPAs), capable of immunomodulating experimental autoimmune uveitis (EAU), induced in B10.RIII mice by immunization with the retinal antigen interphotoreceptor-binding protein in CFA. Alanine-substituted peptides of the major pathogenic epitope, residues 161–180, were synthesized. They were tested for immunogenicity, cross-reactivity with the native 161–180 epitope, pathogenicity, and ability to prevent EAU when given in IFA before EAU challenge with native murine (m)161–180. Two peptides, 169A and 171A, were unable to elicit disease but cross-reacted with m161–180 by lymphocyte proliferation. Mice pretreated with either of the substituted peptides failed to develop EAU after challenge with the native epitope, m161–180, and had reduced cellular responses by lymphocyte proliferation and by delayed hypersensitivity. Their cytokine response profile to m161–180 showed reduced antigen-specific IFN-{gamma} and IL-17, whereas IL-4, IL-5, IL-10, and IL-13 from IPA-protected mice were increased, and serum antibody titers to m161–180 revealed reduced IgG2a and elevated IgG1 isotypes, suggesting a Th2 shift in the response. Protection was transferable with lymphoid cells from protected donors to naïve recipients, who were subsequently immunized for EAU. Thus, IPA pretreatment prevents induction of EAU by skewing the response to a subsequent uveitogenic challenge with the native peptide to a nonpathogenic phenotype, as well as by eliciting transferable regulatory cells.

Key Words: experimental autoimmune uveitis • tolerance






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Leukocyte Biology.